Evidence map›Paper›PMID 40076767›Full record

ArticleInternational journal of molecular sciences2025

Molecular Biological Determination of

Ema Ruszova, Ziad Khaznadar, Zuzana Spurkova, Katerina Vlcanova

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ema RuszovaLaboratory of Clinical Genetics, University Hospital Bulovka, 180 81 Prague, Czech Republic.ORCID 0000-0003-1427-6625
Ziad KhaznadarThe Central Laboratories, University Hospital Bulovka, 180 81 Prague, Czech Republic.
Zuzana SpurkovaDepartment of Anatomical Pathology, University Hospital Bulovka, 180 81 Prague, Czech Republic.
Katerina VlcanovaLaboratory of Clinical Genetics, University Hospital Bulovka, 180 81 Prague, Czech Republic.

Funding

Charles University
6 · The paper itself

Abstract

The immunohistochemical (IHC) or fluorescence/chromogenic in situ hybridization (FISH/CISH) assays for assessing HER2 are now recommended by the American Society of Clinical Oncologists and the College of American Pathologists, but there are an increasing number of published studies describing alternative diagnoses at the molecular level. Inspired by these studies, we established a laboratory-developed test (LDT) to analyze

Indexed as

Breast NeoplasmsDNAErb-b2 Receptor Tyrosine KinasesRNABiomarkers, TumorFemaleGene DosageHumansImmunohistochemistryIn Situ Hybridization, FluorescenceBiomarkers, TumorDNAERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRNAgene copy numbergene expressionHER2/ERBB2quantitative PCR assessment

Identifiers

PMID40076767
PMCPMC11899855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.